Differential Tumor Surveillance by Natural Killer (NK) and NKT Cells

By Mark J. Smyth,* Kevin Y.T. Thia,* Shayna E.A. Street,* Erika Cretney,* Joseph A. Trapani,* Masaru Taniguchi,‡ Tetsu Kawano,‡ Sonja B. Pelikan,§ Nadine Y. Crowe,§ and Dale I. Godfrey§

From the *Cellular Cytotoxicity Laboratory, Austin Research Institute, Austin and Repatriation Medical Centre, Heidelberg, 3084 Victoria, Australia; the ‡Division of Molecular Immunology, Center of Biomedical Sciences, School of Medicine, Chiba University, Chiba 260-8670, Japan; and the §Department of Pathology and Immunology, Monash University Medical School, Prahran, 3181 Victoria, Australia

Abstract

Natural tumor surveillance capabilities of the host were investigated in six different mouse tumor models where endogenous interleukin (IL)-12 does or does not dictate the efficiency of the innate immune response. Gene-targeted and lymphocyte subset–depleted mice were used to establish the relative importance of natural killer (NK) and NK1.1 T (NKT) cells in protection from tumor initiation and metastasis. In the models examined, CD3–NK cells were responsible for tumor rejection and protection from metastasis in models where control of major histocompatibility complex class I–deficient tumors was independent of IL-12. A protective role for NKT cells was only observed when tumor rejection required endogenous IL-12 activity. In particular, T cell receptor Jα281 gene-targeted mice confirmed a critical function for NKT cells in protection from spontaneous tumors initiated by the chemical carcinogen, methylcholanthrene. This is the first description of an antitumor function for NKT cells in the absence of exogenously administered potent stimulators such as IL-12 or α-galactosylceramide.

Key words: tumor immunity • perforin • natural killer T cells • interleukin 12 • carcinogen

Introduction

It is generally accepted that the host immune status, particularly natural immune responses, is essential in controlling the dissemination and growth of metastatic tumors. NK cells mediate spontaneous cytotoxicity against MHC class I–deficient tumor cells and their metastases (1), and they have long been known to participate in the innate immune response against transformed cells in vivo (1, 2). However, only a few studies have reported a prominent role for NK cells on the growth of primary tumors in mice without using biological response modifiers to magnify the response (2, 3). Certainly cytokines, such as type I IFN and IL-12, are considered important in initiating the activation of NK cells in response to pathogens (4). More recently, NKT cells have been isolated and characterized (5–8), and their role in IL-12–mediated antitumor activity has been defined (9).

NKT cells are defined as specialized populations of αβ T cells that coexpress some receptors of the NK cell lineage (5). NKT cells consist mainly of CD4–CD8–double negative and CD4+ cells (6, 7), most of which express a restricted TCR repertoire comprising an invariant Vα14Jα281 TCR α chain (8) associated with polyclonal Vβ8, Vβ7, and Vβ2 TCR β chains. A TCR Jα281 gene-targeted mouse produced by Cui et al. (9) confirmed the requirement of invariant Vα14α281 TCR for the development of most NKT cells (10). These unusual regulatory cells that bridge the innate and acquired immune systems recognize CD1d-bound glycolipid ligands such as α-galactosylceramide (α-GalCer [11, 12]) and glycosylphosphatidylinositols (13). NKT cells are present in most tissues where T cells are found, in particular the liver, bone marrow, spleen, and thymus (14–16). Thymus and liver con-
tain primarily CD1d-dependent Jα281-dependent NKT cells, whereas spleen and bone marrow are enriched in CD1d-independent Jα281-independent NKT cells (17, 18). NKT cells have the peculiar potential to very rapidly secrete large amounts of Th1 and Th2 cytokines (5, 19, 20), but also express perforin and surface molecules such as Fas ligand (21, 22). After culture in the presence of IL-2, NKT cells can mediate lysis through TCR, NK1.1, or CD16, and kill classical N K-sensitive targets such as YAC-1 in vitro (23, 24). The NK1.1 molecule, which activates the cytolytic function of NK cells (25, 26) and IL-2-mediated a similar effect (27).

Perhaps the strongest implication for a role for NKT cells in Th1 immunity is in tumor rejection responses after exogenous IL-12 (9, 28–30) or α-GalCer (11, 31) administration. The in vivo antitumor activity of α-GalCer strongly resembles the antitumor activity mediated by IL-12 (9, 32), and indeed α-GalCer mediates its effects by inducing IL-12 production by dendritic cells (DCs) and IL-12 receptor and IFN-γ expression by NKT cells (33). Although it is likely that endogenously produced IL-12 may also stimulate NKT cells to produce IFN-γ and activate NKT cell cytolytic function, no study to date has evaluated the natural ability (i.e., not exogenously activated by IL-12 or α-GalCer) of NKT cells to reject tumor growth or metastasis. These studies teach us something about the therapeutic benefit and mechanism of IL-12 or α-GalCer, but very little about the natural tumor surveillance capabilities of NKT cells. Here, we have evaluated several tumor rejection model in naïve mice in which endogenous IL-12 does or does not regulate the efficiency of the innate immune response. For the first time, we describe a critical role for NKT cells and endogenous IL-12 in protection from spontaneous tumors initiated by the chemical carcinogen, methylicholanthrene (MCA).

Materials and Methods

Mice. Inbred C57BL/6 (B6) mice were purchased from The Walter and Eliza Hall Institute of Medical Research. B6 TCR Jα281-deficient (B6.Jα281−/−) mice were obtained after eight backcrosses of the (129 × B6)F1 Jα281−/− mice (5) with B6 mice. B6 perforin-deficient (B6.P−/−) mice (34; from Dr. Gunna Karupiah, John Curtin School of Medical Research, Canberra, Australia) and B6 IL-12p40-deficient (B6.12p40−/−) mice (35; Hoffman-La Roche) were bred at the Austin Research Institute Biological Research Laboratories. Mice of 4–8 wk of age were used in all experiments in accordance with Animal Experimental Ethics Committee guidelines.

Cell Culture. The mouse tumor cell lines, YAC-1, R M-1, and EL4-S3 (p2-microglobulin deficient; provided by Dr. James McCluskey, University of Melbourne, Melbourne, Australia) were grown in culture as described previously (36, 37). Sarcomas derived from MCA-treated B6 or B6.Jα281−/− mice were maintained as described above. Flow cytometric sorting of N K, NKT, and T cells was performed using a FACStarPLUS® (Becton Dickinson [18]), and sort purities were always 97% or higher.

Results and Discussion

NK and NKT Cells Numbers in Gene-targeted Mice. Multiparameter flow cytometry was used to examine the status of NK and NKT cells in the various mouse strains used in this study. NKT cells were equivalently present in the thymi of B6, B6.IL-12p40−/−, and B6.P−/− strains, whereas B6.Jα281−/− mice were markedly deficient in NKT cells.
in the thymus (references 9, 17, 18; data not shown). As recently reported (17, 18), NKT cells were also reduced in spleen and liver of B6.1α281−/− mice, but were not completely absent.

IL-12–independent MHC Class I–deficient Tumor Control by NK Cells. Recently, we demonstrated that MHC class I–negative RMA-S tumor growth was controlled in the peritoneum by CD3−NK1.1+ NK cells in a perforin-dependent manner (36). In a similar fashion, EL4-S3 and RM-1 tumor cells inoculated intraperitoneally were cleared less effectively in B6.P-/- mice and B6 mice treated with anti-NK1.1 mAb compared with wild-type B6 mice (Fig. 1, A and B). Rejection was IL-12 independent and did not require T cells, in particular Vα14Jα281+ NKT cells, as evidenced by normal responses in B6.IL-12p40−/− and B6.Jα281−/− mice. Similar requirements have been demonstrated using other MHC class I–deficient tumors, including RMA-S (data not shown). All three cell lines were class I deficient, and expressed low levels (RMA-S) or no (EL4-S3, RM-1) CD1d (data not shown).

Innate Control of Experimental Metastases. Innate protection from metastases was then examined in two different models in which NK1.1+ cells control tumor colonization (29, 37). In the first, we have demonstrated that NKT cells protect B6 mice from experimental EL4-S3 liver metastases in an IL-12–independent fashion (Fig. 2 A). Neither Thy1+ nor specifically Vα14Jα281+ NKT cells appeared to control the number of hepatic colonies growing in EL4-S3–inoculated mice. A significantly greater number of lesions was observed in B6.P-/- mice (P < 0.0001), indicating that NK1.1+ effectors primarily use perforin to re-

Figure 1. Elimination of intraperitoneally administered MHC class I–negative syngeneic tumors in vivo is mediated by NK cells and is IL-12 independent. B6, B6.P-/- (B6.P0), B6.IL-12p40−/− (B6.IL-12p40), or B6.Jα281−/− (B6.Jα2810) mice (five per group) were injected intraperitoneally with tumor cells (10^5) in 0.2 ml PBS, as indicated. Some groups of B6 mice were depleted of NK cells or T cells in vivo by treatment with mAb, 100 μg anti-NK1.1, or anti-Thy1, respectively, on days −2 and 0 (day of intraperitoneal tumor inoculation), and weekly thereafter. Mice were observed daily for tumor growth for 80 d by monitoring the development of ascites in mice. Individual mice are represented by each symbol. (A) EL4-S3 and (B) RM-1.

Figure 2. Innate control by NK and NKT cells in protection from tumor metastases. (A) Groups of five B6, B6.P-/- (B6.P0), B6.IL-12p40−/− (B6.IL-12p40), or B6.Jα281−/− (B6.Jα2810) mice were injected intravenously with 500, 5,000, or up to 50,000 EL4-S3 tumor cells 14 d later, their livers were removed and fixed in Bouin's solution, and surface lung metastases were counted with the aid of a dissecting microscope. Some groups of B6 mice were depleted of NK cells or T cells in vivo, as in the legend to Fig. 1. (B) Groups of five B6, B6.P-/- (B6.P0), B6.IL-12p40−/− (B6.IL-12p40), or B6.Jα281−/− (B6.Jα2810) mice were injected subcutaneously with RM-1 tumor cells (2 × 10^6), and tumors were established for 9 d. At this time, subcutaneous tumors were surgically resected, and RM-1 cells were injected via the dorso-lateral tail vein. Mice were killed 14 d later, the lungs were removed and fixed in Bouin's solution, and surface lung metastases were counted with the aid of a dissecting microscope. Control experiments were performed by inoculating mice with RM-1 cells intravenously and counting lung metastases 14 d later. Some groups of B6 mice were depleted of NK cells or T cells in vivo, as in the legend to Fig. 1. The data for A and B were recorded as the mean (n = 5) number of metastases ± SEM. Significant differences from B6 group were determined by an unpaired t test to determine a two-tail P value (*P < 0.0001; **P < 0.005).
duce EL4-S3 tumor colonization. Clearly, the endogenous response to EL4-S3 was NK cell mediated, and thus these data contrast with previous studies that have suggested that the anti-EL4 activity of exogenous IL-12 was mediated by NKT cells (29).

In a second model, we have demonstrated previously that NK1.1+ cells using perforin protect B6 mice from RM-1 metastasis (37). These studies also indicated that tumor protection was compromised in B6 recombination activating gene 1 (RAG-1)-deficient mice. Here, we have extended these observations to demonstrate that NKT cells are also partially responsible for RM-1 tumor protection.

Interestingly, the number of RM-1 colonies was very similar in B6,α281−/− mice, B6,IL-12p40−/− mice, and B6 mice depleted of T cells with anti-Thy1 mAb (Fig. 2 B). It remains to be determined what role NKT cells play in NK cell-mediated protection from metastasis in this model, but clearly endogenous IL-12 activity was required.

MCA-induced Fibrosarcoma Is Controlled by Vα14 NKT Cells in an IL-12-dependent Manner. Induction of fibrosarcoma by MCA has been demonstrated previously to be controlled by effector cells in a perforin-dependent and IFN-dependent manner (38, 39). To date, however, no extensive analysis has been undertaken to identify the sub-

Figure 3. NKT cells protect mice from MCA-induced sarcoma. Groups of B6, B6.P0−/− (B6.P0), B6,IL-12p40−/− (B6,IL-12p400), or B6,α281−/− (B6,α2810) mice (number of mice in parentheses) were injected subcutaneously in the hind flank with (A) 100 μg or (B) 25 μg MCA diluted in 0.1 ml corn oil. Mice were observed weekly for tumor development over the course of 50–180 d. Tumors >5 mm in diameter and demonstrating progressive growth over 3 wk were counted as positive. Some groups of B6 mice were depleted of NK cells or T cells in vivo, as in the legend to Fig. 1. In C, sarcoma development in B6, B6.P0−/− (B6.P0) and B6,α281−/− (B6,α2810) mice was compared at several doses of MCA with data recorded at 180 d as a percentage of the mice in each group (in parentheses). Significant differences from the B6 group were determined by a Fisher’s exact test (**P<0.005; ***P<0.02). Sarcomas derived from (D) B6,α281−/− mice (α2810-MCA-1) and (E) B6 mice (B6-MCA-1) were transplanted at 106 or 107 cells subcutaneously into groups of five B6,α281−/− or B6 mice. Tumor growth was measured daily with a caliper square as the product of two diameters. Results were recorded as the mean tumor size (in cm2) ± SEM, and are representative of two similar sarcomas transplanted into B6 and B6,α281−/− mice.
Published February 21, 2000

Here, groups of B6 gene-targeted mice were injected subcutaneously with different doses of MCA, and fibrosarcoma development was monitored for a period of 180 d (Fig. 3, A–C). At the doses examined, B6.Jα281+/− mice developed tumors more frequently and earlier than B6 control mice. A high (>70%) percentage of B6.Jα281+/− mice treated with 100 and 25 μg of MCA developed tumors, whereas only small proportions developed tumors in the corresponding wild-type mice receiving MCA. At an MCA dosage of 1 μg, 30% of B6.Jα281+/− mice developed fibrosarcoma, whereas B6 mice remained tumor free (Fig. 3 C). Although IL-12 administration has been demonstrated to protect mice from B6 mice remained tumor free (Fig. 3 C). Although IL-12 administration has been demonstrated to protect mice from B6.Jα281+/− mice treated with a syngeneic MCA-induced fibrosarcoma (38), our data in IL-12p40−/− mice are the first to describe a role for endogenous IL-12 in this model (Fig. 3 A). Further evidence supporting a role for Vα14 NKT cells in the surveillance of MCA-induced tumors was obtained in B6 mice that were chronically depleted of NK1.1+ or Thy1+ cells (Fig. 3 A).

Depletion of CD8+ T cells did not increase the proportion of mice developing fibrosarcoma (data not shown), in concert with a similar study with CD8-deficient mice (38). These data would argue against an important role for CD8+ T cells or CD8+ lymphoid DCs that have been demonstrated to contribute to some NK1.1+ cell-mediated tumor rejection responses driven by Flt3 ligand (41). Nevertheless, Flt3 ligand treatment has been demonstrated previously to cause complete regression of tumors in mice challenged with a syngeneic MCA-induced fibrosarcoma (42), and thus endogenous responses to MCA-induced spontaneous tumors may also involve intermediary DC populations. In agreement with van den Broek et al. (38), B6.P−/− mice were more prone to MCA-induced sarcoma, but always less so than B6.Jα281+/− mice, suggesting that more than one effector mechanism might be employed by NK1.1+ cells in tumor surveillance. Given the demonstrated surveillance defect in IFN-γR−/− deficient mice (39), we are currently evaluating the level of protection in IFN-γ-deficient mice and mice deficient for both perforin and IFN-γ.

In concert with previous studies (38, 43), MCA-induced sarcomas arising in B6 and B6.Jα281+/− mice were generally both MHC class I negative and CD1d− (data not shown). Interestingly, when tumors were transplanted subcutaneously from B6.Jα281+/− mice, they grew far more effectively in B6.Jα281+/− mice than in control B6 mice. Indeed, doses as high as 106 cells were effectively controlled by B6 mice (Fig. 3 D) and (B6 × 129)F1 mice (as a control for any potential minor 129 alloantigen expressed by the tumor; data not shown). By contrast, sarcomas arising in B6 mice grew equally well in B6.Jα281+/− and B6 mice after transfer (Fig. 3 E). This observation is analogous to other studies that have indicated that tumor initiation in immunocompetent mice compared with immunocompromised mice (e.g., B6.Jα281+/− mice) may select for the growth of less immunogenic tumors (43).

NKT Cells Can Directly Lyse Spontaneous SarcomasA rising in MCA-treated Mice. To test the possibility that MCA-induced sarcomas were sensitive to direct lysis by NKT cells, we determined the basal and activated cytotoxicity of NKT cells against MCA-1 (a sarcoma derived from B6.Jα281+/− mice) and other tumor target cells (Fig. 4). Sorted NKT cells from the liver of B6 mice displayed significant lysis of MCA-1 in a 4-h assay, particularly with IL-2/IL-12 stimulation (Fig. 4 A). The lytic activity of sorted resting liver NK cells was higher than resting NKT cells against all the tumor target cells, with RM-1 tumor cells comparatively insensitive to both NK and NKT cells. Thymus NKT cells demonstrated lower levels of lysis of MCA-1 than liver NKT cells, but they too demonstrated enhanced lysis with IL-2/IL-12 stimulation. Although resting NKT cells did not display significantly greater lysis of...
target cells in 18-h assays, both thymus and liver NKT cells stimulated in IL-2/IL-12 over the assay period were considerably more lytic than in the 4-h assay (Fig. 4 B). By contrast, NKT cells sorted from the thymi of B6.P−/− mice were unable to lyse MCA-1, even after IL-2/IL-12 stimulation for 18 h, suggesting that NKT cell lysis of MCA-1 was strictly perforin dependent (Fig. 4 B). Control thymus T cells did not display lytic activity in the absence or presence of IL-2/IL-12 against YAC-1 or MCA-1.

Concluding Remarks. The deficiency of a TCR Vα14 Jα281-expressing NKT cell population in TCR Jα281 gene-targeted mice confirmed a critical function for NKT cells in protection from spontaneous tumors initiated by the chemical carcinogen, MCA. This is the first description of an antitumor function for NKT cells in the absence of endogenously administered IL-12 or α-GalCer. It remains unclear whether NK cells are also contributing directly to protection from MCA-induced sarcoma, as depletion of NKT cells serves to eliminate both NK and NKT cells.

The observations that the frequency of sarcomas is higher in TCR Jα281 gene-targeted mice than in anti-NK1.1 mAb-treated mice, and that anti-NK1.1 mAb treatment did not further increase the frequency of sarcomas in TCR Jα281 gene-targeted mice (data not shown) suggested that NK cells may not necessarily play any additional role. However, the mAb depletion of NK1.1− cells over 6 mo is not optimal, and a mouse deficient in NK cells but not NKT or T cells would offer an ideal model mouse in which to address this issue further.

The question of whether the antitumor activity of exogenous IL-12 is mediated by NKT cells rather than NK cells which to address this issue further.

NKT or T cells would offer an ideal model mouse in not optimal, and a mouse deficient in NK cells but not cooperate previous observations that NK cell–mediated clearance of tumors from the peritoneum is quite a distinct process, dependent strictly on perforin, and requiring TNF for NK cell recruitment (36). In the lung, R M−1 rejection requires NKT cells and IFN-γ (data not shown), but not TNF, and thus it is possible that the cytokine network initiating the NK cell response may be distinct at different tumor sites. Importantly, a recent study by Carnaud et al. (46) has suggested that with the appropriate activation, NKT cells can rapidly produce IFN-γ that activates NK cells.

When comparing sarcoma induction by MCA in B6.P−/− and B6.Jα281−/− mice (Fig. 3 C), it is apparent that additional effector mechanisms may contribute to the protective response. In particular, the response of NKT cells to cytokines (such as IL-12) or production of cytokines (such as IFN-γ) may also provide tumor protection by mechanisms other than perforin-mediated cytotoxicity. Indeed, ongoing experiments in IFN-γ-deficient mice and mice doubly deficient for IFN-γ and perforin support an important role for IFN-γ in addition to perforin (Smyth, M.J., unpublished data). We have demonstrated here that after activation with IL-12, NKT cells can directly lyse MCA-induced tumors with negligible levels of MHC class I or CD1d. This is not to say that NKT cells protect mice from sarcoma development by direct lysis, as NK cells also lyse MCA-1 tumor cells, but the data illustrate that direct tumor cell lysis cannot be ruled out as a potential mechanism of control. It remains to be determined whether TCR-CD1d interactions are involved in direct lysis of MCA tumors by activated NKT cells, and the role of CD1d in surveillance against MCA-induced sarcoma needs to be examined in CD1d-deficient mice. Several recent studies suggest that DCs expressing CD1d may act as important APCs in innate antitumor responses by NK and/or NKT cells (33, 41).

Further work will be required to dissect the dynamics between NK and NKT cells and APCs in vivo in this tumor model.

Our work provides the first evidence that TCR Vα14 Jα281 NKT cells may be critical in natural immune responses to spontaneous tumors. The demonstrated critical role of Vα14 NKT cells in controlling what are considered weakly immunogenic sarcomas raises the question of whether NKT cells may also play an important role in protection from more immunogenic tumors, such as those induced by oncogenic viruses or UV light. Future work evaluating the role of NKT cells in other spontaneous tumor models should provide greater insight into the immune networks that constitute tumor surveillance.

We thank the staff of the Austin Research Institute Biological Research Laboratories for their maintenance and care of the mice in this project.

M.J. Smyth is currently supported by a National Health and Medical Research Council (NHMRC) of Australia Principal Research Fellowship. D.I. Godfrey was supported by the NHMRC and by an AdCorp-Diabetes Australia Postdoctoral Fellowship. This work was supported by an NHMRC Project Grant.

Submitted: 25 August 1999
Revised: 22 November 1999
Accepted: 30 November 1999

References


